Illumina has secured an $8 million damages verdict against China-based BGI Genomics, and its US subsidiary, MGI, in a dispute involving gene-sequencing patents.
The World Intellectual Property Office has launched a course on IP and genetic resources in the life sciences.
The Federal Circuit has affirmed a Patent Trial and Appeal Board decision denying Stanford University a patent application for calculating parent genes.
Stanford University can’t patent a genetic testing method as it is based on “abstract mathematical calculations”, the US Court of Appeals for the Federal Circuit has ruled.
ERS Genomics has agreed to license CRISPR-Cas9 technology to a Barcelona-based start-up which uses a zebrafish-based research model.
Biotech company Illumina has won a dispute with Columbia University, after the Court of Appeals for the Federal Circuit backed an earlier ruling that the university’s DNA-sequencing patents were invalid.
Roche has asked the US Supreme Court to declare that methods of separating DNA are not patent-eligible.
Biotechnology company Ravgen has accused Myriad Genetics and Myriad Women’s Health of infringing two patents covering non-invasive DNA testing technology.
Eli Lilly is expanding its genetics business with the $880 million purchase of Prevail Therapeutics, in a deal that could rise to more than $1 billion.
Pharmaceutical companies Illumina and Roche have been sued for allegedly infringing two patents covering the technology for non-invasive DNA testing by Maryland genetic testing company Ravgen.